Overview: Actos, a Type 2 diabetes medication manufactured by Takeda Pharmaceuticals, is once again being blamed for a case of bladder cancer. According to a lawsuit filed by the national law firm of Parker Waichman LLP, a Pennsylvania man developed bladder cancer after starting the drug in 2009. The lawsuit is one of thousands pending in the Actos multidistrict litigation, where Jerrold S. Parker, founding partner of Parker Waichman LLP, has been appointed to the Plaintiff’s Steering Committee.
- Parker Waichman LLP has filed a lawsuit on behalf of a Pennsylvania man alleging Actos caused bladder cancer; the suit was filed on February 5th in the U.S. District Court for the Western District of Louisiana, Lafayette Division
- The lawsuit alleges that the Defendants knew about the risk of bladder cancer but failed to warn the Plaintiff or the public
- The FDA has warned that using Actos for more than a year could increase the risk of bladder cancer
Product: Actos (pioglitazone)
Manufacturer: Takeda Pharmaceutical
Side Effects & Complications
- Bladder cancer
- Heart attacks
- Congestive heart failure
Actos Allegedly Caused Bladder Cancer
The Plaintiff began taking Actos in 2009. By March 2011, he was diagnosed with bladder cancer. The lawsuit alleges that Actos caused the bladder cancer and that the Defendants failed to warn about these risks. He is suing for a number of damages as an alleged result of using Actos, including severe mental and physical pain and suffering, permanent injuries, emotional distress and economic loss. Allegedly, the Plaintiff would never have taken Actos if he were fully aware of the risks.
The lawsuit was filed on February 5th in the U.S. District Court for the Western District of Louisiana, Lafayette Division where it is one of many cases pending in the Actos multidistrict litigation entitled In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). Jerrold S. Parker, founding partner of Parker Waichman LLP, serves on the Plaintiff’s Steering Committee in the litigation. Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc. f/k/a Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company have been named as Defendants.
Actos was approved in 1999 to treat patients with Type 2 diabetes. In June 2011, the U.S. Food and Drug Administration (FDA) warned that Actos may raise the risk of bladder cancer after only one year of use. At around the same time, use of the drug was suspended in France and Germany due to this association. According to a study published in the Journal of the National Cancer Institute, using Actos and other medications in the thiazolidinedione class could raise the risk of bladder cancer when used as a long-term therapy. In July 2012, the Canadian Medical Association Journal published a study showing that Actos is linked to a 22 percent increased risk of bladder cancer. In light of this mounting evidence, a number of Actos users have come forward to file lawsuits against the manufacturer of the drug.